Restricted accessResearch articleFirst published online 2018-2
Development of high-affinity monoclonal antibody using CD44 overexpressed cells as a candidate for targeted immunotherapy and diagnosis of acute myeloid leukemia
CD44s antigens have been suggested as an efficient biomarker for cancer stem cells. Current study aimed to develop a hybridoma that producing a high affinity murine anti-human CD44 monoclonal antibody for early diagnostic laboratory tests of some cancer.
MATERIALS AND METHODS:
To make hybridoma against CD44, mice were immunized with MDA-MB-468 cells. Resulted hybridomas using three culture media were screened by indirect ELISA, then cloned by limiting dilution, and isotype was determined after obtaining ascitic fluid and antibody purification.
RESULTS:
We obtained a stable secreting clone, capable of secreting a high-affinity monoclonal antibody against CD44 protein, IgG2a kappa, with the affinity of 5.4 × 10-8 M without cross-reactivity.
CONCLUSION:
We could establish a hybridoma in a native form. This stable and high-affinity anti-CD44 mAb has a potential for diagnostic procedures and laboratory research. Thus, it could be exploited as a suitable tool for target-specific diagnosis and even treatment in several cancers.
P.Klingbeil, R.Natrajan, G.Everitt, R.Vatcheva, C.Marchio, J.Palacios, H.Buerger, J.S.Reis-Filho and C.M.Isacke, CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification, Breast Cancer Res Trt120 (2010), 95-109.
3.
I.Morath, T.Hartmann and V.Orian-Rousseau, CD44: More than a mere stem cell marker, The Int J Biochem Cell Biol, 2016.
4.
R.Sneath and D.Mangham, The normal structure and function of CD44 and its role in neoplasia, Mol Pathol51 (1998), 191-200.
5.
J.M.Reichert and V.E.Valge-Archer, Development trends for monoclonal antibody cancer therapeutics, Nat Rev Drug Discov6 (2007), 349-356.
6.
B.Cate, M.de Bruyn, Y.Wei, E.Bremer and W.Helfrich, Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology, Curr Drug Targets11 (2010), 95-110.
7.
J.Liu and G.Jiang, CD44 and hematologic malignancies, Cell Mol Immunol3 (2006), 359-365.
8.
D.M.Lewinsohn, A.Nagler, N.Ginzton, P.Greenberg and E.C.Butcher, Hematopoietic progenitor cell expression of the H-CAM (CD44) homing-associated adhesion molecule, Blood75 (1990), 589-595.
9.
S.Pandey, Hybridoma technology for production of monoclonal antibodies, Hybridoma1 (2010), 17.
10.
Z.Gadhoum, J.Delaunay, E.Maquarre, L.Durand, V.Lancereaux, J.Qi, J.Robert-Lezenes, C.Chomienne and F.Smadja-Joffe, The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells, Leuk Lymphoma. 45 (2004), 1501-1510.
11.
K.Takeuchi, A.Yamaguchi, T.Urano, T.Goi, G.Nakagawara and H.Shiku, Expression of CD44 variant exons 8-10 in colorectal cancer and its relationship to metastasis, Jpn J Cancer Res86 (1995), 292-297.
12.
J.Gao, M.Wu, J.Gao, X.Wang, Y.Zhang, S.Zhu, Y.Yu and W.Han, Generation and Characterization of a New Monoclonal Antibody Against CXCL4, Monoclon Antib Immunodiagn Immunother34 (2015), 110-115.
13.
P.Martineau, Affinity measurements by competition ELISA, Antibody Engineering (2010), 657-665.
14.
M.Habibi-Anbouhi, K.Azadmanesh, M.Behdani, E.Hajizadeh-Saffar, R.Vahabpour and M.A.Shokrgozar, Development and Characterization of a New Antipeptide Monoclonal Antibody Directed to Human CD20 Antigen, Cancer Biother Radiopharm30 (2015), 310-316.
15.
J.D.Beatty, B.G.Beatty and W.G.Vlahos, Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay, J Immunol Methods100 (1987), 173-179.
16.
J.G.Jurcic, Antibody therapy of acute myelogenous leukemia, Cancer Biother Radio15 (2000), 319-326.
17.
R.Majeti, Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells, Oncogene30 (2011), 1009-1019.
18.
F.L.Coco, E.Ammatuna and N.Noguera, Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin, Clin Adv Hematol Oncol4 (2006), 57-62.
19.
V.Orian-Rousseau and H.Ponta, Perspectives of CD44 targeting therapies, Arch Toxicol89 (2015), 3-14.
20.
J.Zhou and W.-J.Chng, Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia, World J Stem Cells6 (2014), 473-484.
21.
P.Bernasconi, M.Farina, M.Boni, I.Dambruoso and C.Calvello, Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?Am J Hematol91 (2016), 507-517.
22.
L.Jin, K.J.Hope, Q.Zhai, F.Smadja-Joffe and J.E.Dick, Targeting of CD44 eradicates human acute myeloid leukemic stem cells, Nat Med12 (2006), 1167-1174.
23.
S.Nedvetzki, M.Walmsley, E.Alpert, R.O.Williams, M.Feldmann and D.Naor, CD44 involvement in experimental collagen-induced arthritis (CIA), J Autoimmun13 (1999), 39-47.
24.
M.P.Shepley and V.R.Racaniello, A monoclonal antibody that blocks poliovirus attachment recognizes the lymphocyte homing receptor CD44, J Virol68 (1994), 1301-1308.
25.
J.W.Stroomer, J.C.Roos, M.Sproll, J.J.Quak, K.-H.Heider, B.J.Wilhelm, J.A.Castelijns, R.Meyer, M.O.Kwakkelstein and G.B.Snow, Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients, Clin Cancer Res6 (2000), 3046-3055.
26.
N.L.Van Hal, G.A.van Dongen, S.V.Walsum, G.B.Snow and R.H.Brakenhoff, Characterization of cd44v6 isoforms in head-and-neck squamous-cell carcinoma, Int J Cancer82 (1999), 837-845.
27.
S.Zarei, A.A.Bayat, R.Hadavi, A.R.Mahmoudi, B.Tavangar, Y.Vojgani, M.Jeddi-Tehrani and Z.Amirghofran, Production and characterization of a peptide-based monoclonal antibody against CD44 variant 6, Monoclon Antib Immunodiagn Immunother34 (2015), 36-43.
28.
M.Bashyal Insan and V.Jaitak, New approaches to target cancer stem cells: current scenario, Mini Rev Med Chem14 (2014), 20-34.
29.
R.S.Charrad, Z.Gadhoum, J.Qi, A.Glachant, M.Allouche, C.Jasmin, C.Chomienne and F.Smadja-Joffe, Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines, Blood99 (2002), 290-299.
30.
L.da Cruz, N.Chouinard, N.Feng, D.Sayegh, D.Pereira, D.Rubinstein, S.Hahn and D.Young, Preclinical development of huARH460-16-2, a humanized antibody to the CD44 cancer stem cell target, Can Res68 (2008), 3975-3975.
31.
D.Young, H.Findlay, S.Hahn, L.Cechetto and F.McConkey, Chimeric and humanized Anti-CD44 antibodies that mediate cancer cell cytotoxicity, WO 2008144890 A1 Patent2 (2008).
32.
F.J.Darfler, Protein-free culture medium which promotes hybridoma growth. Google Patents, 1991.
33.
J.Zhang and D.Robinson, Development of animal-free, protein-free and chemically-defined media for NS0 cell culture, Cytotechnology48 (2005), 59-74.
34.
N.Vijayasankaran, J.Li, R.Shawley, A.Chen, M.Shiratori, M.Gawlitzek, F.Li, R.Kiss and A.Amanullah, Animal cell culture media, Encyclopedia of Industrial Biotechnology, 2010.
35.
D.A.Epstein, P.J.Battista, D.F.Gruber and D.A.Judd, Metal binding compounds and their use in cell culture medium compositions. Google Patents, 2004.
36.
D.Inlow, B.Maiorella and W.Howarth, Cell culture medium for enhanced cell growth, culture longevity, and product expression. Google Patents, 2000.
